SuperGen’s PIM Kinase Inhibitor, SGI-1776, Effective in Pre-Clinical Models of Acute Lymphoblastic Leukemia
/in 2008, News /by webadminAstex presents updates on AT7519 and AT9283 at the American Society of Hematology (ASH) Conference
/in 2008, News /by webadminSuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor
/in 2008, News /by webadminSuperGen’s MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
/in 2008, News /by webadminCancer Research UK and Astex Therapeutics Join Forces to Develop New Anti-Cancer Treatment
/in 2008, News /by webadminSuperGen Granted Orphan Drug Designation for MP-470 in Glioblastoma Multiforme
/in 2008, News /by webadminCopyright © Astex Pharmaceuticals
All rights reserved
Useful links
Member of the Otsuka Group